Regal Assets Analytics

Bioxcel Rockets After Suntrust Upgrade; Agile Volatile Ahead Of FDA Decision

By |2020-03-30T10:12:21-04:00February 14th, 2020|Tags: , |

BioXcel Therapeutics (NASDAQ:BTAI) soared this morning to about $38 per share after a SunTrust analyst placed a $150 price target [...]

Go to Top